CIRM Funded Clinical Trials
A Phase 2 Study Evaluating the Efficacy and Safety of IV Administered rAAV9 Vector Containing RP-A501 in Male Patients with Danon Disease
Disease Area:
Danon Disease, Pediatrics
Trial Sponsor:
Rocket Pharmaceuticals, Inc.
Trial Stage:
Phase 2
Trial Status:
Launching
Targeted Enrollment:
N/A
